Using DNA nanomachines to detect microRNA in blood for pancreatic cancer diagnosis
The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer.
This study is testing a new way to use DNA nanomachines to find specific markers in the blood that could help doctors diagnose pancreatic cancer earlier and more accurately.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Trial ID | NCT06497777 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of DNA nanomachines to detect specific microRNAs in the blood as potential biomarkers for pancreatic cancer. It aims to develop a fluorescence sensing platform that utilizes isothermal nucleic acid amplification technology, which allows for detection without the need for expensive temperature control instruments. By focusing on pancreatic ductal adenocarcinoma, the study seeks to improve the accuracy and efficiency of early diagnosis through innovative detection methods. The approach combines circular strand displacement amplification with DNA nanomachines for enhanced signal amplification at a constant temperature.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with pancreatic ductal adenocarcinoma who have not yet received any anti-cancer therapies.
Not a fit: Patients with active malignancies other than pancreatic adenocarcinoma or those who have undergone anti-cancer therapies for pancreatic cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a more accessible and efficient method for early detection of pancreatic cancer, potentially improving patient outcomes.
How similar studies have performed: While the use of microRNAs as biomarkers has been explored in other studies, this specific approach utilizing DNA nanomachines and isothermal amplification is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pancreatic ductal adenocarcinoma * Proven by pathology * Patients who have not received anti-cancer therapies Exclusion Criteria: * Less than 20 years old * Unable to provide inform and consent * Patients who have active malignancy other than pancreatic adenocarcinoma * Patients who have had pancreatic cancer whose anti-cancer therapies are completed or undergoing * Life expectancy less than 3 months
Where this trial is running
Taipei
- National Taiwan University Hospital — Taipei, Taiwan (Recruiting)
Study contacts
- Study coordinator: Weng Fai Wong, Master of Science
- Email: 106290@ntuh.gov.tw
- Phone: 886-972652272
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.